NCT Number: NCT00150098
Project UNITY - HIV Risk Reduction and Vaccine Education Interventions
To determine the efficacy of an enhanced HIV risk reduction intervention delivered concurrently with a vaccination schedule to reduce the number of unprotected vaginal and anal sex acts among HIV-negative, high-risk non-injection drug-using (NIDU) women. To determine the efficacy of an enhanced vaccine education intervention delivered at baseline to increase vaccine knowledge and understanding of a potential HIV vaccine among HIV-negative, high-risk NIDU women.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
Primary location
New York Blood Center, New York, United States
About this study
We are currently screening women (approximately 535) from whom we expect 400 HIV-negative high-risk, non-pregnant NIDU women will be enrolled to participate in a two-arm randomized trial of an enhanced HIV risk reduction intervention plus an enhanced vaccine education intervention compared to controls. At screening, women complete an assessment, receive HIV and HBV pre-test counseling, and are tested for HIV antibody, markers of hepatitis B virus (HBV) infection and pregnancy. At the enrollment visit (2 weeks later), eligible and willing participants are randomized to receive either the enhanced HIV risk reduction intervention plus the enhanced vaccine education intervention or control conditions. Enrolled women provide urine for pregnancy testing. Enrolled women found to be susceptible to HBV are offered hepatitis B (HB) vaccine at the enrollment visit. Follow-up visits coincide with the HB vaccine schedule (1 and 6 months post enrollment) for all women, regardless of whether or not they received HB vaccine. Pregnancy testing is conducted at these follow-up visits. Participants provide sera for HIV antibody testing at the 6- and 12-months visits. A final visit will occur at 12 months post enrollment to assess longer term effects on risk behaviors and knowledge and understanding of vaccine concepts. All standardized interviews are conducted using Audio Computer Assisted Self-Interview (ACASI) technology.
The enhanced HIV risk reduction intervention is a series of three, interactive, individually-delivered, counseling sessions. The enhanced sessions also include tailored male and female condom demonstrations to build skills, and each session concludes with a client-initiated sexual risk reduction goal. The follow-up sessions (at 1 and 6 months) resume by reviewing goal attainment, exploring the reasons and beliefs associated with progress toward that goal. The control group receives the client-centered HIV counseling based on the Centers for Disease Control and Prevention (CDC) Project RESPECT model. Both the control and enhanced risk reduction counseling are delivered at the baseline (time 0) and at follow up visits (1 month and 6 months).
The enhanced vaccine education component will test the two-session model informed consent process outlined by Coletti et al but enhanced with simplified illustrated educational material delivered through flipcharts, video and individual counseling at baseline and 1 week later. The control condition is based on the Coletti two-session informed consent process.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- at least 18 years of age;
- non-injecting use of heroin, cocaine or crack cocaine in the last six months;
- unprotected vaginal sex in the last three months;
- test HIV antibody negative;
- agree to provide specimens for testing (HIV, HBV and pregnancy) and be willing to learn the results of these tests;
- ability to understand spoken English or Spanish;
- agree to be randomized;
- willing to return for visits at 1, 6, and 12 months post-enrollment;
- willing and able to provide informed consent.
Exclusion criteria
- history of injection drug use in the previous 3 years;
- pregnant;
- intending to become pregnant in the next 12 months.
Treatment and study plan
Primary outcomes
-
- an HIV risk score, the Vaginal Episode Equivalent (VEE)
Time frame: approved prior to 12-1-12
-
- understanding assessment for HIV vaccines.
Time frame: approved prior to 12-1 2012
Secondary outcomes
-
-frequency of use of specific drugs
Time frame: approved prior to 12-1-12
-
-knowledge of HB vaccine acceptance of hepatitis B vaccine among those susceptible
Time frame: approved prior to 12-1-12
-
-adherence to hepatitis B vaccination schedule
Time frame: approved prior to 12-1-12
-
-willingness to participate in HIV vaccine trials
Time frame: approved prior to 12-1-12
-
-measures of motivators and barriers to receiving hepatitis B vaccine and a candidate HIV vaccine
Time frame: approved prior to 12-1-12
-
-incidence of pregnancy
Time frame: approved prior to 12-1-12
Sponsors and collaborators
Lead sponsor
New York Blood Center
Other
Collaborators
- Rutgers University
- The New York Academy of Medicine
Registry information
Official study title
Project UNITY - A Randomized Trial of Enhanced HIV Risk Reduction and Vaccine Education Interventions in Reducing Sexual Risk and Increasing Vaccine Trial Knowledge Among HIV-negative, High-risk Women Who Use Non-injection Drugs
Important dates
- Study start
- 2005
- Primary completion
- 2009
- Study completion
- 2010
- First posted
- Sep 8, 2005
- Registry last updated
- Apr 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
NCT05551273
Blood-Borne Infections, Communicable Diseases
San Diego, California, United States
View Trial DetailsEstimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center
NCT05127187
Blood-Borne Infections, Communicable Diseases
Nîmes, France
View Trial DetailsInvestigating Point-of-care Diagnostics for Sexually Transmitted Infections and Antimicrobial Resistance in Primary Care in Zimbabwe
NCT05541081
Bacterial Infections, Bacterial Infections and Mycoses
Harare, Zimbabwe
View Trial DetailsProject MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community
NCT04947475
Actinomycetales Infections, Bacterial Infections
Bishkek, Kyrgyzstan
View Trial Details